# CHEMICAL HERITAGE FOUNDATION

# **MATTHEW L. MEYERSON**

The Pew Scholars Program in the Biomedical Sciences

Transcript of an Interview Conducted by

Karen A. Frenkel

at

Dana-Farber Cancer Institute and the Broad Institute Boston and Cambridge, Massachusetts

on

17, 18, and 19 January 2006

From the Original Collection of the University of California, Los Angeles



# Matthew L. Meyerson

# ACKNOWLEDGEMENT

This oral history is part of a series supported by a grant from the Pew Charitable Trusts based on the Pew Scholars Program in the Biomedical Sciences. This collection is an important resource for the history of biomedicine, recording the life and careers of young, distinguished biomedical scientists and of Pew Biomedical Scholar Advisory Committee members.

This oral history was completed under the auspices of the Oral History Project, University of California, Los Angeles (Copyright © 2007, The Regents of the University of California) and is made possible through the generosity of



#### From the original collection at the Center for Oral History Research, UCLA Library, UCLA.

The following oral history, originally processed at the UCLA Center for Oral History Research, has been reformatted by the Chemical Heritage Foundation. The process involved reformatting the front matter, adding a new abstract, replacing the table of contents, and replacing the index. The paragraph spacing and font of the body of the transcript were altered to conform to the standards of the Oral History Program at the Chemical Heritage Foundation. The text of the oral history remains unaltered; any inadvertent spelling or factual errors in the original manuscript have not been modified. The reformatted version and digital copies of the interview recordings are housed at the Othmer Library, Chemical Heritage Foundation. The original version and research materials remain at the Darling Library, University of California, Los Angeles and at the Bancroft Library, University of California, Berkeley.

#### **REFORMATTING:**

Kim Phan, Program Intern, Oral History, Chemical Heritage Foundation. B.A. expected 2011, Anthropology, Cornell University.

David J. Caruso, Program Manager, Oral History, Chemical Heritage Foundation. B.A., History of Science, Medicine, and Technology, Johns Hopkins University; PhD., Science and Technology Studies, Cornell University.



In exchange for the UCLA Library's Center for Oral History Research conducting and recording the series of interviews with me beginning on or about January 17, 2006, I, Matthew Meyerson, do hereby give all right, title, and interest, including copyright, in and to those interviews to the Regents of the University of California and grant that they may be used for any research, educational, or other purpose that the University may deem appropriate. I understand that I may still use the information in the recordings myself without seeking permission from the University.

I have read and agree to the Center for Oral History Research's Use Policy, which outlines the current and likely future uses of interviews donated to the Center's collection.

Unless otherwise specified above, I place no restrictions on access to and use of the interviews.

Interviewce (Signature)

Matthew Meyerson M.D.

(Typed Name)

Dana Farber Cancer Instsitute, 44 Binney Strreet, Dana 15, Boston, Massachusetts 02115 (Address)

617.632.4768

B102406E

(Phone Number)

matthew\_meyerson@dfci.harvard.edu (E-mail Address)

\_\_\_\_\_

July 27, 2006 (Date)

Signed on behalf of the Regents of the University of California:

Head, UCLA Library's Center for Oral History Research

Teresa Barnett (Typed Name)

(310) 206-2454 (Phone Number)

10/20/06 (Date)

tbarnett@library.ucla.edu (E-mail Address)

This interview has been designated as Free Access.

One may view, quote from, cite, or reproduce the oral history with the permission of CHF.

*Please note*: Users citing this interview for purposes of publication are obliged under the terms of the Chemical Heritage Foundation Oral History Program to credit CHF using the format below:

Matthew L. Meyerson, interview by Karen A. Frenkel at the Dana-Farber Cancer Institute and the Broad Institute, Boston and Cambridge, Massachusetts, 17-19 January 2006 (Philadelphia: Chemical Heritage Foundation, Oral History Transcript # 0618).



Chemical Heritage Foundation Oral History Program 315 Chestnut Street Philadelphia, Pennsylvania 19106



The Chemical Heritage Foundation (CHF) serves the community of the chemical and molecular sciences, and the wider public, by treasuring the past, educating the present, and inspiring the future. CHF maintains a world-class collection of materials that document the history and heritage of the chemical and molecular sciences, technologies, and industries; encourages research in CHF collections; and carries out a program of outreach and interpretation in order to advance an understanding of the role of the chemical and molecular sciences, technologies, and industries; and industries in shaping society.

# **MATTHEW L. MEYERSON**

1963	Born in Boston, Massachusetts, on 4 June
	Education
1985 1993 1994	A.B., Chemistry & Physics, Harvard College M.D., Harvard Medical School Ph.D., Biophysics, Harvard University
	Professional Experience
1994-1996 1998-present	Massachusetts General Hospital, Boston, Massachusetts Residency in Clinical Pathology; Consultant in Pathology
1995-1998	Whitehead Institute, Cambridge, Massachusetts Research fellow in Biology; Robert Weinberg Laboratory,
1998-2005	Harvard Medical School, Boston, Massachusetts Assistant Professor of Pathology,
1998-2004 1998-2005 2005-present	Dana-Farber Cancer Institute, Boston, Massachusetts Scientific co-director, Belfer Center for Cancer Genomics Assistant Professor of Pathology, Associate Professor of Pathology
2004-present	Harvard-MIT Division of Health Sciences and Technology Member of the Affiliated Faculty
2004-present	Broad Institute, Cambridge, Massachusetts Associate Member
	<u>Honors</u>

1987-1993	Medical Scientist Training Program Fellowship
1990-1991	Johnson and Johnson HST Research Fellowship
1995-1998	Damon Runyon-Walter Winchell Foundation Physician-Scientist
	Fellowship
1998-2001	Claudia Adams Barr Investigator Award, Dana-Farber Cancer Institute

#### Selected Publications

- Tsai L-H, Harlow E, Meyerson M. Isolation of the human cdk2 gene that encodes the cyclin Aand adenovirus E1A-associated p33 kinase. Nature 1991; 353: 174-177.
- Meyerson M, Enders G, Wu C-L, Su L-K, Gorka C, Nelson C, Harlow E, Tsai L-H. A family of human cdc2-related protein kinases. EMBO Journal 1992; 11: 2909-2917.
- Meyerson M, Harlow E. Identification of G1 kinase activity for cdk6, a novel cyclin D partner. Molecular and Cellular Biology 1994; 14: 2077-2086.
- Counter CM, Meyerson M, Eaton EN, Weinberg RA. The catalytic subunit of yeast telomerase. Proc Natl Acad Sci USA 1997; 94: 9202-9209.
- Meyerson M, Counter CM, Eaton EN, Ellisen LW, Steiner P, Caddle SD, Ziaugra L, Beijersbergen RL, Davidoff MJ, Liu Q, Bacchetti S, Haber DA, Weinberg RA. hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization. Cell 1997; 90: 785-795.
- Counter CM, Meyerson M, Eaton EN, Ellisen LW, Caddle SD, Haber DA, Weinberg RA. Telomerase activity is restored in human cells by ectopic expression of hTERT (hEST2), the catalytic subunit of telomerase. Oncogene 1998; 16: 1217-1222.
- Kolquist KA, Ellisen LW, Counter CM, Meyerson M, Tan LK, Weinberg RA, Haber DA, Gerald WL. Expression of TERT in early premalignant lesions and a subset of cells in normal tissues. Nature Genetics 1998; 19: 182-186.
- Hahn, W. C., Stewart, S. A., Brooks, M. W., York, S. G., Eaton, E., Kurachi, A., Beijersbergen, R. L., Knoll, J. H., Meyerson, M. and Weinberg, R. A. Inhibition of telomerase limits the growth of human cancer cells. Nature Medicine 1999; 5: 1164-1170.
- Stanton, E.S., Shin, S.W., Johnson, B.E., and Meyerson, M. Recurrent allelic deletions of chromosome arms 1 5q and 1 6q in human small cell lung carcinomas. Genes Chromosomes & Cancer 2000; 27: 323-33 1.
- Lindblad-Toh, K., Tanenbaum, D.M., Daly, M.J., Winchester, E., Liu, X., Villapakkam, A., Stanton, S.E., Larsson, C., Hudson, T.J., Johnson, B.E., Lander, E.S. and Meyerson, M. Allelotyping of small cell lung cancer using single nucleotide polymorphism arrays. Nat Biotechnology 2000; 18: 1001-1005.
- Bhattacharjee, A., Richards, W.G., Staunton, J., Li, C., Monti, S., Vasa, P., Ladd, C., Beheshti, J., Bueno, R., Gillette, M., Loda, M., Weber, G., Mark, E., Lander, E.S., Wong, W., Johnson, B.E., Golub, T.R., Sugarbaker, D.J., and Meyerson, M. Classification of human lung carcinomas by mRNA expression analysis. Proceedings of the National Academy of Sciences of the United States of America 2001; 98: 13790-13795.
- Weber, G., Shendure, J., Tanenbaum, D.M., Church, G.M. and Meyerson, M. Identification of foreign gene sequences by transcript filtering against the human genome. Nature Genetics 2002; 30: 141-142.
- Naoki, K., Chen, T., Richards, W.G., Sugarbaker, D.J. and Meyerson, M. Missense mutations of the BRAF gene in human lung adenocarcinoma. Cancer Research 2002; 62: 7001-7003.
- Xu, Y. Stange-Thomann, N., Weber, G. Bo, R., Dodge, S., David, R.G., Foley, K., Beheshti, J.,

Harris, N.L., Birren, B., Lander, E.S. and Meyerson, M. Pathogen discovery from human tissue by sequence-based computational subtraction. Genomics 2002; 81: 329-335.

- Lieberfarb, M., Lin, M., Lechpammer, M., Li, C., Tanenbaum, D.M., Writht, R., Shim, J., Kantoff, P.W., Loda, M., Meyerson, M., and Sellers, W.R. 2003. Genome-wide lossofheterozygosity analysis from laser-capture microdissected prostate cancer using SNP arrays and a novel bioinformatics platform dCHIPSNP. Cancer Research 63, 2003; 63: 478 1-4785.
- Wang ZC, Lin M, Wei LJ, Li C, Miron A, Lodeiro G, Harris L, Ramaswamy S, Tanenbaum DM, Meyerson M, Iglehart JD, Richardson A. Loss of heterozygosity and its correlation with expression profiles in subclasses of invasive breast cancers. Cancer Res 2004; 64: 64-71.
- Scacheri PC, Rozenblatt-Rosen O, Caplen NJ, Wolfsberg TG, Umayam L, Lee JC, Hughes CM, Shanmugam KS, Bhattacharjee A, Meyerson M, Collins FS. Small interfering RNAs can induce unexpected and divergent changes in the levels of untargeted proteins in mammalian cells. Proc Natl Acad Sci USA 2004; 101: 1892-1897.
- Hughes CM, Rozenblatt-Rosen O, Milne TA, Copeland TD, Levine SS, Lee JC, Hayes DN, Shanmugam KS, Bhattacharjee A, Biondi CA, Kay GF, Hayward NK, Meyerson M. Menin associates with a trithorax family histone methyltransferase complex and with the Hoxc8 locus. Mol Cell 2004; 13: 587-597.
- Janne PA, Li C, Zhao X, Girard L, Chen TH, Minna J, Christiani DC, Johnson BE, Meyerson M. High-resolution single nucleotide polymorphism array and clustering analysis of loss of heterozygosity in human lung cancer cell lines. Oncogene 2004; 23: 2716-2726.
- Zhao X, Li C, Paez JG, Chin K, Janne PA, Chen TH, Girard L, Minna J, Christiani D, Leo C, Gray JW, Sellers WR, Meyerson M. An integrated view of copy number and allelic alterations in the cancer genome using single nucleotide polymorphism arrays. Cancer Res 2004; 64: 3060-3071.
- Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE, Meyerson M. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304: 1497-1500.
- Paez JG, Lin M, Beroukhim R, Lee JC, Zhao X, Richter DJ, Gabriel S, Herman P, Sasaki H, Altshuler D, Li C, Meyerson M, Sellers WR. Genome coverage and sequence fidelity phi29 polymerase-based multiple-strand displacement whole-genome amplification. Nucl Acids Res 2004; 32:e71.
- Jiang J, Paez JG, Lee JC, Bo R, Stone RM, DeAngelo DJ, Galinsky I, Wolpin BM, Jonasova A, Herman P, Fox EA, Boggon TJ, Eck MJ, Weisberg E, Griffin JD, Gilliland DG, Meyerson M, Sellers WR. Identification and characterization of a novel activating mutation of the FLT3 tyrosine kinase in AML. Blood 2004; 104: 1855-1858.
- Tengs T, LaFramboise T, Den RB, Hayes DN, Zhang J, DebRoy S, Gentleman RC, O'Neill K, Birren B, Meyerson M. Genomic representations using concatenates of Type IIB restriction endonuclease digestion fragments. Nucleic Acids Res. 2004; 32: e121.
- Rozenblatt-Rosen O, Hughes CM, Nannepaga SJ, Shanmugam KS, Copeland TD, Guszczynski T, Resau JH, Meyerson M. The parafibromin tumor suppressor protein is part of a human Paf1 complex. Mol Cell Biol. 2005 Jan;25(2):612-20.
- Milne TA, Hughes CM, Lloyd R, Yang Z, Rozenblatt-Rosen O, Dou Y, Schnepp RW, Krankel C, Livolsi VA, Gibbs D, Hua X, Roeder RG, Meyerson M, Hess JL. Menin and MLL cooperatively regulate expression of cyclin-dependent kinase inhibitors. Proc Natl Acad Sci U

S A. 2005 Jan 18;102(3):749-54. Epub 2005 Jan 7.

#### ABSTRACT

**Matthew L. Meyerson** was born in Boston, Massachusetts, the youngest of three children. His family moved several times before finally settling in Philadelphia, Pennsylvania, when Matthew was seven. His parents were both academics in city planning and then college professors. His father became president of State University of New York at Buffalo and then the University of Pennsylvania; he was the first Jewish president of a major university. His mother taught sociology and then was on Philadelphia's City Planning Commission. Meyerson's interest in science began early: he loved to collect rocks and minerals and thought he might become a geologist. His first influential teacher was his fourth-grade teacher, who had the students do science experiments. His ninth-grade biology teacher was especially inspiring. His extracurricular activities included fencing, at which he was competitive; running; and exploring the outdoors. He also played the piano. He read extensively and still loves to read.

He decided early to attend Harvard University. College experiences included an overwhelming math class that cemented his resolve to become an experimental scientist, rather than a theoretical scientist. He did research on quinones during college in Leslie Dutton's laboratory at the University of Pennsylvania and on enzyme evolution in Steven Benner's laboratory at Harvard. He spent a year in Japan at the University of Kyoto and then began medical school.

Meyerson entered the joint health sciences and technology graduate program at Harvard University and Massachusetts Institute of Technology. His medical school experiences included meeting his future wife, who was also a medical student. Meyerson pursued doctoral research on cyclin-dependent kinases involved in cell-cycle regulation in Edward Harlow's laboratory at Harvard. He did his residency in clinical pathology. Meanwhile, he and his wife, by now doing her own residency in pediatrics, began their family, which eventually grew to four children. Meyerson accepted a postdoctoral fellowship on cell immortalization in Robert Weinberg's laboratory at Massachusetts Institute of Technology (MIT). Here he discusses the running of the Harlow lab; the process of conducting scientific research; his collaboration with Christopher Counter at MIT on telomerase genes in yeast; and his work in cell-cycle genetics identifying human telomerase gene activity and cell immortalization. He compares Weinberg's mentoring style with his own.

Meyerson accepted a position at the Dana-Farber Cancer Institute and set up his lab to accord with his decision to work on lung-cancer genetics. He talks about the running of his lab and about his funding history. Meyerson discusses his research on cancer genomics, functional biochemistry, and computational subtraction genetic analysis; and broader applications of his work genetically targeting drug treatment for lung cancer.

Meyerson's current research is focused on genomics sequencing cancer causing mutations. He talks about the process of writing journal articles; his role in the lab and his management style; his teaching responsibilities and philosophy; science versus religion; foreign students in science; and being a principal investigator. He answers questions about the grant-writing process; how he would go about setting the national science agenda; his view of the issue of patents; and David Livingston's mentorship. Meyerson concludes by explaining his professional and personal goals and talking about the difficulty balancing family and career.

#### UCLA INTERVIEW HISTORY

#### **INTERVIEWER:**

Karen A. Frenkel, Interviewer, UCLA Oral History Program; B.A., Hampshire College, 1978; M.S., Boston University, 1982

#### TIME AND SETTING OF INTERVIEW:

**Place:** Matthew Meyerson's offices at Dana-Farber Cancer Institute, Boston, MA, and at the Broad Institute, Cambridge, MA.

#### Total number of recorded hours: 4.5

Persons present during interview: Meyerson and Frenkel.

#### CONDUCT OF INTERVIEW:

This interview is one in a series with Pew Scholars in the Biomedical Sciences conducted by the UCLA Oral History Program in conjunction with the Pew Charitable Trusts' Pew Scholars in the Biomedical Sciences Oral History and Archives Project. The project has been designed to document the backgrounds, education, and research of biomedical scientists awarded four-year Pew scholarships since 1988.

To provide an overall framework for project interviews, the director of the UCLA Oral History Program and three UCLA faculty project consultants developed a topic outline. In preparing for this interview, Frenkel held a telephone pre-interview conversation with Meyerson to obtain written background information (curriculum vitae, website address, copies of published articles, etc.) and agree on an interviewing schedule. She also reviewed the documentation in Meyerson's file at the Pew Scholars Program office in San Francisco, including his proposal application, letters of recommendation, and reviews by Pew Scholars Program national advisory committee members.

#### ORIGINAL EDITING

Carol Squires edited the interview. She checked the verbatim transcript of the interview against the original tape recordings, edited for punctuation, paragraphing, and spelling, and verified proper names. Words and phrases inserted by the editor have been bracketed.

Meyerson did not review the transcript. Consequently, some proper names and other information remain unverified.

Carol Squires prepared the table of contents. Technitype Transcribing compiled the guide to proper names.

#### **TABLE OF CONTENTS**

Family background. Childhood interests and experiences. Early interest in

# science. Influential teachers in grade school and high school. His siblings. Attends high school at Andover, Massachusetts. Extracurricular activities. Religion. Attends Harvard University. College experiences. Research during college in Leslie Dutton's laboratory at the University of Pennsylvania and Steven Benner's laboratory at Harvard. Year in Japan at the University of Kyoto. Challenges of a career in science. Medical School, Graduate School, and Postdoctoral Work Attends an M.D./Ph.D. program held jointly at Harvard University and

Massachusetts Institute of Technology. Joint health sciences and technology graduate program. Medical school experiences. Meets future wife. Doctoral research on cyclin-dependent kinases involved in cell-cycle regulation in Edward Harlow's laboratory at Harvard. Residency in clinical pathology. Harlow's mentoring style. Postdoctoral fellowship on cell immortalization in Robert Weinberg's laboratory at Massachusetts Institute of Technology (MIT). Process of conducting scientific research. Collaboration at MIT with Christopher Counter on telomerase genes in yeast. Work in cell-cycle genetics identifying human telomerase gene activity and cell immortalization. Robert Weinberg's mentoring style.

Dana-FarberCancer Institute and Research

Childhood and College

Accepts a position at the Dana-Farber Cancer Institute. Setting up lab. Decision to work on lung-cancer genetics. Funding history. Research on cancer genomics, functional biochemistry, and computational subtraction genetic analysis. Collaborations. Broader application of work genetically targeting drug treatment for lung cancer. Current research in genomics sequencing cancer causing mutations. Writing journal articles. Role in the lab.

Laboratory Life and Thoughts about Science

Lab management style. Teaching responsibilities. Teaching philosophy. Science and religion. Foreign students as science graduate students and postdoctoral fellows. Grant-writing process. Setting the national science agenda. Patents. David Livingston's mentorship. Balancing family and career. The percentage of women as graduate students and principal investigators. Professional and personal goals.

Index

1

17

52

73

#### INDEX

## A

Academy of Natural Sciences, 2 acquired immunodeficiency syndrome, 23 Agencourt [now Beckman Coulter Genomics], 67 AIDs. *See* acquired immunodeficiency syndrome American Cancer Society, 91 American Lung Association, 61 Amsterdam, Netherlands, 35 *Arrowsmith*, 7 Asimov, Isaac, 2, 7

#### B

Barr Program, 74 Baylor College of Medicine, 44 Benner, Steven, 11, 12, 13, 16, 20, 51 Berens, Anton, 35 Berkeley, California, 1 Bernstein, Alan, 35 Beverly, Massachusetts, 67 Bhattacharjee, Arindam, 62 Boston Lying-In Hospital, 1 Boston, Massachusetts, 1, 68 BRAF, 68, 69 Brigham and Women's Hospital, 29, 70 Broad Institute, 62, 67, 69, 72, 83, 91, 92, 93, 99, 102 Bryn Mawr College, 9 Buffalo, New York, 1 Bush, President George W., 89, 90 Bush, Reed, 3, 4

# С

CD4 protein, 23 CDC2, 26, 27 CDK2. See cyclin-dependent kinase 2 cdk3. See cyclin-dependent kinase 3 CDK3. See cyclin-dependent kinase 3 cdk6. See cyclin-dependent kinase 6 Cech, Thomas, 11, 45, 47 Cell, 40 cell cycle, 24, 25, 26, 27, 35 China, 89 Church, George, 65, 66 Clinton, President William J., 90 Clonetech, 42, 48 Cold Spring Harbor Laboratory, 24, 26, 27 collaboration, 62, 63, 67, 70, 72, 78 Collins, Kathleen, 41 Colorado, 2 Columbia University, 9 competition, 6, 7, 17, 33, 94, 101, 103 Copernicus, 84 Counter, Christopher, 25, 41, 44, 46, 47, 49, 51, 52, 53 Crohn's disease, 4 cyclin, 25, 26, 27, 28 D-type cyclin, 28, 35 cyclin-dependent kinase 2, 25, 26, 27 cyclin-dependent kinase 3, 27, 28 cyclin-dependent kinase 6, 28, 35

# D

Damon Runyon-Walter Winchell Foundation Physician-Scientist Fellowship, 54 Dana-Farber Cancer Institute, 1, 21, 40, 52, 54, 55, 56, 57, 59, 60, 62, 68, 70, 72, 74, 75, 82, 83, 91, 92, 96, 97, 98, 99 Davis, Alice, 3, 4 DNA, 24, 26, 38, 42, 44, 65, 66, 96 cDNA, 64 *Drosophila*, 27 Duke University, 20, 47 Dutton, Leslie, 10, 11

# Е

Eaton, Elinor, 42 *EGFR. See* epidural growth factor receptor England, 8, 68 epidural growth factor receptor, 69, 70, 71, 72, 78, 90, 91, 96, 97 Epstein-Barr virus, 65 Europe, 8, 12 European Molecular Biology Organization, 27, 28 evolution, 11, 21, 87

# F

*FA6*, 69 Factor V Leiden, 30 Fazeli, Amin, 40 France, 8

#### G

Galilei, Galileo, 84 Genentech Inc., 23 genomics, 24, 60, 62, 66, 69, 93 Genzyme, 96 Gilbert, Walter, 23, 24, 32, 59 Gleevec, 67, 68 Golub, Todd, 62 grants/funding, 55, 58, 60, 61, 67, 68, 73, 74, 89, 90, 91, 92, 93, 94, 101 Greece, 8

#### Η

Hahn, William, 51 Hanahan, Douglas, 35 Hanes, Tom, 11 Harlow, Edward, 24, 25, 26, 27, 30, 32, 33, 34, 36, 37, 38, 51, 52, 53, 59 Harvard Medical School, 25, 58, 77, 82 Harvard University, 1, 9, 10, 12, 13, 20, 24, 44, 58, 65, 66, 75, 76, 78, 81, 82, 83, 101 Harvard Yard, 10 Harvard-MIT Division of Health Sciences and Technology, 20, 65 Hi, Ron, 67 HIV. See human immunodeficiency virus Horowitz, Paul, 11 Houseman, David, 82 Hughes, Christina, 64, 77 human immunodeficiency virus, 23, 24 human papilloma virus, 65, 86

#### Ι

Iressa gefitinib drug, 69

# J

Jacks, Tyler, 35 Janne, Pasi, 70 Japan, 12, 13, 14, 16, 26, 49, 69, 70, 78 Jenkins, Farris, 21 Johns Hopkins University, 20 Johnson, Bruce, 60, 62, 70

#### K

Kansas, 86 Klausner, Richard, 94 Kyoto University, 14, 20, 27

#### L

Lander, Eric, 60, 62, 67, 72 Lee, Jeff, 69 Lewis, Sinclair, 7 Lindeman, Neal, 70 Livingston, David, 59, 60, 62, 68, 74, 97, 98 Lundblad, Victoria, 44, 45 lung cancer, 21, 22, 57, 58, 60, 62, 66, 69, 70, 71, 72, 90, 94, 95, 96

# Μ

Maryland, 10 Massachusetts, 52 Massachusetts General Hospital, 22, 24, 29, 30, 71, 96 Massachusetts Institute of Technology, 20, 22, 25, 30, 35, 44, 54, 65, 81 menin protein, 21, 62, 64, 77, 90 Merck & Co., 54, 55 Meyerson, Jacob (son), 7, 14, 28, 100, 101 Meyerson, Olivia (daughter), 7, 14, 28, 29, 100, 101 Meyerson, Phoebe (daughter), 7, 14, 28, 100, 101 Meyerson, Sophia (daughter), 7, 14, 28, 100, 101 MIT. See Massachusetts Institute of Technology

*MIT-1*, 44 Mt. Monadnock, 52 multiple endocrine neoplasia, 21, 62

# Ν

Nadler, Lee, 59 National Cancer Institute, 93 National Institutes of Health, 53, 60, 61, 89, 90, 91, 92, 93, 94 Nature, 25, 27, 39, 44 Nature Biotechnology, 62 Nature Genetics, 65 neurobiology, 10, 23 New England Journal of Medicine, 72 New Hampshire, 52 NIH. See National Institutes of Health Nine West, 74 Nobel Prize, 78 Northern blot, 43, 48 Novartis, 68, 96, 97 Novartis Research Foundation, 74, 98

## 0

Oloff, Ellen, 54

# P

Paez, J. Guillermo, 67, 69
patents, 96
pathology, 22, 28, 29, 30, 35
PCR. See polymerase chain reaction
Penn Charter School, 3
Pew Scholars Program in the Biomedical Sciences, 1, 32, 61, 62, 76, 88, 90
Philadelphia, Pennsylvania, 1, 2, 3, 6
Philanthropy Roundtable, 4
Phillips Academy, 6
Pollack, Nellie, 97
polymerase chain reaction, 25, 48
Princeton University, 9
publish/publication, 12, 16, 27, 37, 39, 40, 45, 46, 47, 51, 62, 65, 71, 72, 73, 101

# Q

quinone, 11, 12

#### R

religion, 13, 84, 85, 86, 87, 88, 95 Jew/Jewish/Judaism, 1, 7 RNA, 43, 44, 48, 49, 65 Robinson, Jackie, 1 Rozenblatt-Rosen, Orit, 63, 64, 77 Russia, 8

# S

San Francisco, California, 35 Science, 40, 45, 72 Scotland, 8 Seattle, Washington, 78, 79 Sellers, William, 62, 66, 69, 72, 97, 98 Shendure, Jay, 65, 66 Sicinski, Peter, 55 Singapore, 39 single nucleotide polymorphism, 60, 62 Skolnick, Ed, 54 Southern blot, 38, 41 Stanton, Sasha, 62 State University of New York, Buffalo, 1 Summers, Lawrence H., 101 Switzerland, 68

# Т

telomerase, 41, 44, 45, 46, 47, 48, 49, 51, 52, 54, 57 telomere, 41, 48 tenure, 101 *Tetrahymena*, 41 thrombophilia, 30 Tokyo, Japan, 14 Tonegawa, Susumu, 22 Toronto, Ontario, Canada, 35 Tsai, Li-Huei, 25

# U

United States of America, 6, 20, 58, 83, 88 University of California, Berkeley, 1 University of Chicago, 9 University of Colorado, 45 University of Pennsylvania, 1, 4, 10, 20 University of Washington, 78

# V

Varmus, Harold E., 90, 94

# W

Waring, Allan, 4 Washington, D.C., 4, 10 Weber, Griffin, 65, 66 Weinberg, Robert A., 30, 35, 36, 37, 40, 43, 47, 48, 50, 51, 52, 53, 54, 55, 59, 60 Wellcome Trust Sanger Institute, 68 Whitehead Institute, 53, 60, 62, 67, 68, 69 Whitehead Institute Center for Genome Research, 62 Wissahicken Creek, 2

# Y

Yale University, 9 Yugoslavia, 8